Ratos owns 95% of the capital and votes in Biolin Scientific after the extended acceptance period
This information is disclosed in accordance with the Securites Markets Act and NASDAQ OMX Stockholm's rules regarding public offers on the stock market.
This press release may not be distributed, directly or indirectly, in or into, Australia, Canada, Japan, New Zealand, South Africa, Switzerland or the United States of America. The Offer is not being made to (and acceptances will not be accepted from) persons in those countries or in any other country where the making of the Offer, the distribution of this press release or acceptance of the Offer requires further offer documents, filings or other measures in addition to those required by Swedish law. Ratos owns a total of 25 264 243 shares and convertibles, corresponding to 95.05% of all shares and votes in Biolin Scientific following the end of the extended acceptance period. Settlement in respect of shareholders that accepted the offer during the extended acceptance period is expected to commence on 19 January 2011. The acceptance period is further extended until 24 February 2011. Based on the final review of acceptances received during the extended acceptance period, which ended on 12 January 2011, an additional 1 218 761 shares and convertibles, corresponding to 4.59% of all shares and votes in Biolin Scientific, have been tendered in the offer. This means that the offer has been accepted by owners of a total of 24 642 835 shares and convertibles, corresponding to 92.71% of the capital and votes in Biolin Scientific. Together with 621 408 shares, corresponding to 2.34% of the capital and votes, acquired outside the offer on NASDAQ OMX at a price of SEK 11.50 per share since 30 December 2010, Ratos now owns 25 264 243 shares and convertibles in Biolin Scientific, corresponding to 95.05% of all capital and votes (after full dilution). Consequently, Ratos has through the acquisitions of shares on NASDAQ OMX reached an ownership above 90% (after full dilution) excluding the shares tendered in the extended acceptance period. To enable participation in the offer by those shareholders who have not yet accepted the offer, the acceptance period is extended once more until 24 February 2011 at 17:00 CET. For those who accept the offer during this extra extension of the acceptance period, settlement is expected to commence on 3 March 2011. Since Ratos holds more than 90% of the capital and votes in Biolin Scientific, Ratos intends shortly to initiate compulsory acquisition of the remaining shares in Biolin Scientific and to promote a delisting of Biolin Scientific`s shares from NASDAQ OMX Stockholm. For further information, please contact: Arne Karlsson, CEO, +46 70 379 79 79 Emma Rheborg, Head of Corporate Communications & IR, +46 8 700 17 20 Financial calendar from Ratos: Year-end report 2010 17 February 2011 Annual General Meeting 2011 5 April 2011 Interim Report January - March 2011 5 May 2011 Interim Report January - June 2011 19 August 2011 Interim Report January - September 2011 9 November 2011 Ratos is a private equity conglomerate. The company`s mission is to maximise shareholder value over time through the professional, active and responsible exercise of its ownership role in primarily medium to large unlisted Nordic companies. Ratos`s holdings include AH Industries, Anticimex, Arcus Gruppen, Biolin Scientific, Bisnode, Contex, DIAB, EuroMaint, GS-Hydro, Hafa Bathroom Group, HL Display, Inwido, Jøtul, KVD Kvarndammen, Lindab, Medisize, Mobile Climate Control, SB Seating, Stofa, Superfos and Other holdings. Ratos is listed on NASDAQ OMX Stockholm and market capitalisation amounts to approximately SEK 42 billion.